Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
United HealthCare agreed to cover Mvasi and Kanjinti in a preferred position. Amgen VP-oncology sales & marketing Susan Logan talked to Scrip about the company's first US biosimilar launches.
The company updated investors on the launch of the first treatment for postpartum depression during its Q2 earnings call. More than 100 sites have been certified under the REMS.
Many multinationals are banking on novel drug products to capture China’s new growth spurt as it transforms to care centered on innovative therapies, although this could be a hard sell given the largely private pay nature of the market for such products. Q2 China growth at Merck & Co. however flew through the roof with the aid of a suite of newly launched products. So what made it a shining star?
The decision to expand the HPV vaccination program in England to boys comes as Merck & Co sees "an unprecedented increase in global demand" for Gardasil.
Local knowledge on the regulatory and commercial fronts is an absolute must to succeed in Europe, Patrick Mahaffy tells Scrip a couple of months after the firm's PARP inhibitor Rubraca hit the German market.
As China enters a new growth spur for the health sector, underscored by faster product approvals, annual reimbursement coverage and strong demand for high-quality treatments, strategic planning and meticulous execution are more important than ever if companies want to win in the world's second-largest pharma market, says a new report.
Traditionally a low-cost manufacturing haven, China has seen pharma R&D costs increase rapidly although prices for pharmaceuticals have not gone up, forcing officials and executives to explore value assessment and market access approaches in a toughening environment.
The total cost of Zolgensma is more than $2m – in line with estimates – or $425,000 annually for five years if payers choose an annuity-like payment plan. Novartis is also negotiating value-based reimbursement agreements for infants treated with the one-time infusion.
The 20 major companies in the Access to Medicines Index have made progress in areas like inclusive business models, R&D prioritization and equitable pricing, but not enough is being done to develop new medicines for less profitable diseases or to support flexibilities such as compulsory licensing, says a new report from the Access to Medicine Foundation.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.